Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Amyloid imaging for dementia in Canada.

Literature DB >> 27067816

Amyloid imaging for dementia in Canada.

Robert Laforce¹, Mohamed Réda Bensaïdane².

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 27067816 PMCID： PMC4868609 DOI： 10.1503/cmaj.150663

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

Keyword Cloud
References

× No keyword cloud information.

11 in total

1. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

Authors: Thomas G Beach; Sarah E Monsell; Leslie E Phillips; Walter Kukull
Journal: J Neuropathol Exp Neurol Date: 2012-04 Impact factor: 3.685

2. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.

Authors: Robert Laforce; Pedro Rosa-Neto; Jean-Paul Soucy; Gil D Rabinovici; Bruno Dubois; S Gauthier
Journal: Can J Neurol Sci Date: 2016-02-26 Impact factor: 2.104

3. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

Authors: G D Rabinovici; H J Rosen; A Alkalay; J Kornak; A J Furst; N Agarwal; E C Mormino; J P O'Neil; M Janabi; A Karydas; M E Growdon; J Y Jang; E J Huang; S J Dearmond; J Q Trojanowski; L T Grinberg; M L Gorno-Tempini; W W Seeley; B L Miller; W J Jagust
Journal: Neurology Date: 2011-11-30 Impact factor: 9.910

4. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

Authors: Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Andrew Ward; Willem Huijbers; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal: Neurology Date: 2014-04-18 Impact factor: 9.910

5. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

Authors: Keith A Johnson; Satoshi Minoshima; Nicolaas I Bohnen; Kevin J Donohoe; Norman L Foster; Peter Herscovitch; Jason H Karlawish; Christopher C Rowe; Maria C Carrillo; Dean M Hartley; Saima Hedrick; Virginia Pappas; William H Thies
Journal: Alzheimers Dement Date: 2013-01 Impact factor: 21.566

6. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal: Lancet Neurol Date: 2014-09-04 Impact factor: 44.182

Amyloid imaging for dementia in Canada.

1. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

2. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.

3. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

4. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

5. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.

6. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

7. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications.

Review 8. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease.

9. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4).

10. Clinical Utility of Amyloid Imaging in a Complex Case of Corticobasal Syndrome Presenting with Psychiatric Symptoms.